|1.||Prostatic Neoplasms (Prostate Cancer)
|3.||Spinal Cord Injuries (Spinal Cord Injury)
|4.||Hypertension (High Blood Pressure)
|1.||Burnett, Arthur L: 64 articles (09/2015 - 05/2003)|
|2.||Hellstrom, Wayne J G: 62 articles (04/2015 - 11/2002)|
|3.||Montorsi, Francesco: 59 articles (11/2014 - 09/2002)|
|4.||Mulhall, John P: 45 articles (07/2015 - 02/2002)|
|5.||Bivalacqua, Trinity J: 38 articles (06/2015 - 03/2003)|
|6.||Maggi, Mario: 36 articles (04/2015 - 12/2005)|
|7.||Lue, Tom F: 34 articles (04/2015 - 02/2002)|
|8.||Porst, Hartmut: 31 articles (01/2015 - 03/2003)|
|9.||Seftel, Allen D: 29 articles (01/2016 - 09/2002)|
|10.||Kadowitz, Philip J: 28 articles (09/2015 - 04/2003)|
|1.||sildenafil (Viagra)FDA Link
03/01/2006 - "A combined approach of sildenafil and sex therapy proved highly effective in treatment of honeymoon impotence of psychogenic origin; however, controlled studies are needed. "
10/01/2009 - "Sildenafil citrate 50 mg is the recommended starting dose for men with erectile dysfunction (ED); however, most men are later titrated to sildenafil 100 mg for improved efficacy. "
08/01/2005 - "Sildenafil, a highly selective inhibitor of PDE 5, is effective in the treatment of erectile dysfunction. "
07/01/2005 - "Most of the available data on efficacy for sildenafil are based on a questionnaire and erectile dysfunction (ED) is classified with minor or severe organic factors. "
04/01/2004 - "Sildenafil, a highly selective inhibitor of phosphodiesterase type 5, is effective in the treatment of erectile dysfunction. "
|2.||tadalafil (Cialis)FDA Link
12/01/2014 - "Tadalafil is a potent and selective phosphodiesterase type 5 inhibitor that provides effective treatment for erectile dysfunction (ED). "
01/01/2013 - "Tadalafil showed good efficacy and safety for improving LUTS and erectile dysfunction in men with BPH, and 5 mg of tadalafil significantly improved Qmax."
11/01/2012 - "Tadalafil significantly improved treatment satisfaction on the Erectile Dysfunction Inventory of Treatment Satisfaction (P < .001 vs placebo at end point) and psychosocial outcomes on the Self-Esteem and Relationship (SEAR) questionnaire (least squares mean difference in SEAR total score change from baseline, 11.8 [95% confidence interval, 5.4%-18.2%; P < .001 vs placebo]). "
11/01/2011 - "Tadalafil significantly improved the International Index of Erectile Function-Erectile Function score in sexually active men with erectile dysfunction (ED; 6.7 vs 2.0; p<0.001) at 12 wk (not assessed at week 1). "
10/01/2008 - "Tadalafil (2.5 mg) significantly improved the International Prostate Symptom Score obstructive subscore and the International Index of Erectile Function-Erectile Function domain, the latter in sexually active men with a history of erectile dysfunction. "
|3.||vardenafil (Levitra)FDA Link
01/01/2011 - "Vardenafil is a potent and highly selective oral phosphodiesterase type 5 (PDE-5) inhibitor that has been shown in numerous clinical trials and post-marketing surveillance studies to be safe and effective for improving erectile function in men with erectile dysfunction (ED). "
11/01/2010 - "Vardenafil (levitra, Bayer Schering Pharna, Germany) is a 5-phosphodiesterase inhibitor which proved highly effective and safe in the treatment of erectile dysfunction. "
01/01/2006 - "Vardenafil was well tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression. "
07/01/2004 - "Vardenafil is a selective and highly potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), with improved selectivity for PDE5 and demonstrated efficacy for improving sexual function in men with ED. "
01/01/2012 - "The efficacy of on-demand vardenafil ODT 10 mg was established in the POTENT I and II studies, which were 6-week, randomized, double-blind, multinational trials in men with erectile dysfunction of at least 6 months duration. "
|4.||Phosphodiesterase 5 InhibitorsIBA
07/01/2007 - "Mapping the 3D-QSAR models to the active site of PDE5 provides a new insight into the protein-inhibitor interactions and helpful in designing potent and selective PDE5 inhibitors for the treatment of erectile dysfunction."
10/01/2015 - "In the analysis, we found significantly improved IELT in the combination use group compared with the use of SSRIs (mean differences [MD], 1.01; 95% confidence interval [CI], 0.61-1.41; P <.01) or PDE-5 inhibitors alone (MD, 1.11; 95% CI, 0.79-1.43; P <.01) for PE whether or not these patients suffered from erectile dysfunction. "
11/01/2013 - "The phosphodiesterase type 5 (PDE5) inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. "
03/01/2011 - "Although improved nerve-sparing techniques have reduced the incidence of nerve injury, and the administration of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction, this problem remains a considerable challenge. "
08/01/2006 - "Of the current options available to treat erectile dysfunction, oral phosphodiesterase type 5 (PDE5) inhibitors are the recommended first-line treatment. "
|5.||Alprostadil (Muse)FDA LinkGeneric
12/01/2000 - "MUSE was effective and safe in most patients with erectile dysfunction in this study. "
12/01/1998 - "These data of the world-wide longest running prospective trial with a vasoactive drug in self-injection therapy provided impressive proof that Alprostadil-Alfadex represents a very effective and safe treatment for erectile dysfunction of both psychogenic and organogenic origin."
08/01/2001 - "Although MUSE is an appropriate and safe treatment for many patients with erectile dysfunction, the lack of consistency is a significant consideration. "
08/01/2001 - "To determine the consistency of a successful response to intraurethral prostaglandin E(1) (MUSE), an effective treatment for a proportion of patients with erectile dysfunction, during at-home use in men who had a successful response in the office, to define the factors that correlated with the consistency of the response, and to determine whether patients continued long-term use. "
12/01/1997 - "Due to the superior efficacy and lower side-effects self-injection therapy with Alprostadil remains the 'Gold Standard' in the management of male impotence. "
|6.||Type 5 Cyclic Nucleotide PhosphodiesterasesIBA
05/01/2013 - "Inhibition of phosphodiesterase-5 (PDE5) is a well-known mechanism for the effective treatment of erectile dysfunction (ED). "
10/01/2005 - "Conflicting information exists regarding the long-term efficacy of phosphodiesterase-5 (PDE5) inhibitor therapy for erectile dysfunction, particularly in regard to whether therapeutic resistance occurs. "
08/24/2006 - "Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones and their analogues, potentially useful for the treatment of erectile dysfunction, were synthesized and evaluated as inhibitors of phosphodiesterase 5 (PDE5). "
04/01/2002 - "In view of the clinical efficacy of phosphodiesterase-5 inhibitors, activation of sGC may provide an alternative means for enhancing the activity of neurally derived NO during sexual stimulation in the corpus cavernosum, representing a novel approach for the treatment of erectile dysfunction."
01/01/2012 - "The study's primary aim should be to investigate the efficacy of phosphodiesterase-5 inhibitors for treating male erectile dysfunction. "
|7.||Testosterone (Sustanon)FDA Link
03/01/2003 - "Patients given testosterone supplementation experienced a subjective improvement in their wellbeing, but reported no significant improvement in their erectile dysfunction. "
08/01/2000 - "Our meta-analysis of the usefulness of androgen replacement therapy for erectile dysfunction indicates that the response rate for a primary etiology was improved over that for a secondary etiology, transdermal testosterone therapy was more effective than intramuscular or oral treatment, and intramuscular and oral treatments were equivalent. "
04/01/2001 - "Topical treatment with cream containing testosterone and vasoactive agents may represent a new effective treatment for erectile dysfunction associating with aging."
07/01/2007 - "The aim of the trial was assessment of efficacy of combined therapy with testosterone drug (androgel) and wardenafil in patients with erectile dysfunction (ED) and metabolic syndrome (MS). "
09/01/2006 - "Although, it has been difficult to establish correlations between 'andropausal' symptoms and plasma testosterone levels, there is some evidence that testosterone replacement leads to improvement in muscle strength, bone mineral density, and erectile dysfunction. "
10/01/1991 - "The findings suggest that I-C papaverine, although effective in treating impotence, is not a panacea, and a large percentage of users (55% in our study) are likely to discontinue the drug within a relatively short period of time."
01/01/1992 - "The results suggest that measurement of corporal clearance of Tc-RBC after intracorporal injection of papaverine may be a useful method in detecting venous leak, and could be used as a screening test in patients with erectile dysfunction."
02/01/1995 - "This study was done as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of a topical papaverine gel in the treatment of erectile dysfunction. "
02/01/1990 - "Five patients recovered from erectile dysfunction and 1 patient showed papaverine-induced full erection. "
01/01/1990 - "A simple test to predict the outcome of intracavernous papaverine treatment would be helpful in the management of erectile dysfunction. "
03/01/2002 - "To determine the risk-benefit ratio of a forced dose-escalation regimen (2 to 3 to 4 mg) in a European clinical study evaluating apomorphine sublingual (SL) in treating erectile dysfunction (ED), by evaluating the overall tolerability and efficacy of the regimen compared with placebo in patients with ED, and evaluating efficacy by assessing the proportion of successful attempts resulting in sexual intercourse. "
05/01/1998 - "Four of the patients reported erectile dysfunction before beginning apomorphine and two of these report a significant improvement in their sexual function resulting from apomorphine use. "
10/01/2001 - "Sublingual (SL) apomorphine (2 to 6 mg) has been shown to be effective for treatment of male erectile dysfunction. "
08/01/2001 - "The development process for apomorphine SL as an effective treatment for patients with erectile dysfunction has been somewhat unusual. "
01/01/2001 - "Apomorphine SL (Ixense, Uprima) is a new oral medication shown to be effective in the treatment of erectile dysfunction. "
03/01/1997 - "Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? "
02/01/1998 - "The meta-analysis demonstrated that yohimbine is superior to placebo in the treatment of erectile dysfunction (odds ratio 3.85, 95% confidence interval 6.67 to 2.22). "
03/01/1997 - "Yohimbine is no better than placebo as a first-line treatment for mixed-type impotence."
12/01/1996 - "Based on the data to date, yohimbine does not appear to be effective for organic erectile dysfunction and, thus, it should not be recommended as treatment for the standard patient. "
08/22/1987 - "Yohimbine is a safe treatment for psychogenic impotence that seems to be as effective as sex and marital therapy for restoring satisfactory sexual functioning."
|1.||Prostatectomy (Retropubic Prostatectomy)
04/01/2009 - "Even 20% of those patients who did not have a nerve preservation got satisfactory erections, Our experience shows that early penile rehabilitation seems to be a good treatment for erectile dysfunction after radical prostatectomy with IPDE5 in fixed doses. "
04/01/1997 - "Nerve-sparing procedures helped reduce the high incidence of impotence that occurs in patients after radical retropubic prostatectomy. "
11/01/2014 - "Erectile dysfunction (ED) is a major complication after radical prostatectomy (RP); however, debate continues regarding the efficacy of penile rehabilitation in the recovery of the postoperative erectile function (EF). "
01/01/2010 - "Penile injection has been shown to be an effective treatment for erectile dysfunction (ED) following prostatectomy, yet it is not commonly used by these men. "
06/01/2013 - "A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy."
|2.||Penile Prosthesis (Penile Implants)
06/01/2014 - "Device reliability has improved to the point that penile implants are among the most durable mechanical surgical products that contribute to patient and partner satisfaction, which is by far the greatest among all the treatments of erectile dysfunction."
01/01/1997 - "Although penile prostheses are highly effective in the treatment of erectile dysfunction, a small percentage of patients are dissatisfied. "
09/01/1991 - "In view of the alternative treatment options available, the use of alloplastics is now regarded as a last option in the treatment of erectile dysfunction; however, even in 1991 penile implants give the best results known so far."
05/01/1991 - "Penile implants remain the gold standard for the management of erectile impotence, especially complete impotence. "
03/01/1998 - "In contrast, penile prostheses appear to offer a more permanent cure for erectile dysfunction. "
|3.||Drug Therapy (Chemotherapy)
07/01/1993 - "Several classes of smooth muscle relaxing agents have proven effective in relaxing cavernosal smooth muscle and useful in the pharmacotherapy of erectile dysfunction. "
08/01/1988 - "Vasoactive intracavernous pharmacotherapy is an effective treatment for impotence of various etiologies, and in a carefully selected group of patients the acceptance of and satisfaction with this therapy are high."
05/01/2003 - "To evaluate the ability of the five-item version of the International Index of Erectile Function (IIEF-5) to diagnose the vascular aetiology and severity of erectile dysfunction (ED), and to compare it with pharmacological testing and duplex Doppler ultrasonography, as such questionnaires are widely used by the pharmaceutical industry to categorize the severity of ED and to assess the efficacy of drug therapy. "
07/01/2002 - "When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. "
04/01/1999 - "With the availability of safe and effective oral drug therapy, the field of erectile dysfunction has expanded rapidly to encompass multiple disciplines and specialties. "
12/01/1989 - "Recently, intracavernous injections of vasoactive medications have proved beneficial for treating patients with erectile dysfunction. "
01/01/1987 - "Their therapeutic value is reduced to the method by self injections, new treatment for impotence, even if it concerns only few impotent patients. "
06/01/2001 - "Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men."
12/01/1996 - "In this study, the VED was no more effective than injections in overcoming erectile dysfunction, but the relative advantages of either treatment needs to be addressed in controlled clinical trials."
04/01/1994 - "The aim of this study was to assess the effectiveness and safety of intracavernous injections of a four-drug vasoactive mixture in diabetic patients with organic impotence. "
08/01/2011 - "The mechanisms of radiation-induced erectile dysfunction (ED) are unclear, as clinical studies are limited, and previous animal models were based on wide-field irradiation, which does not model current radiotherapy (RT) techniques. "
02/01/2011 - "Preclinical studies of radiotherapy (RT) induced erectile dysfunction (ED) have been limited by radiation toxicity when using large fields. "
09/01/2010 - "In the studies that compared surgery versus radiotherapy, the results were better for radiotherapy (3-72% erectile dysfunction). "
08/30/2003 - "A total of 406 patients with erectile dysfunction reported in their medical records who had completed external beam radiotherapy at least 6 months prior to the study, were approached by letter. "
08/06/2013 - "Treatment modality also influenced patients' stated preferences (P<0.05), whereas the risk of erectile dysfunction due to radiotherapy was mainly important to urologists (P<0.05). "